Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Assets (2020 - 2025)

Maxcyte (MXCT) has disclosed Assets for 6 consecutive years, with $202.5 million as the latest value for Q4 2025.

  • Quarterly Assets fell 15.44% to $202.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $202.5 million through Dec 2025, down 15.44% year-over-year, with the annual reading at $202.5 million for FY2025, 15.44% down from the prior year.
  • Assets for Q4 2025 was $202.5 million at Maxcyte, down from $213.5 million in the prior quarter.
  • The five-year high for Assets was $291.0 million in Q1 2022, with the low at $93.1 million in Q2 2021.
  • Average Assets over 5 years is $250.5 million, with a median of $266.7 million recorded in 2023.
  • The sharpest move saw Assets surged 448.71% in 2021, then decreased 15.44% in 2025.
  • Over 5 years, Assets stood at $284.1 million in 2021, then grew by 0.89% to $286.7 million in 2022, then dropped by 6.41% to $268.3 million in 2023, then fell by 10.74% to $239.5 million in 2024, then dropped by 15.44% to $202.5 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $202.5 million, $213.5 million, and $219.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.